Stock Analiz

Heron Therapeutics, Inc. HRTX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.31Market cap $59M
Open the interactive analysis →

Heron Therapeutics, Inc. (HRTX) is a healthcare company listed in the US with a market value of about $59M. In the twelve months to September 30, 2026 it had revenue of $148M and net income of -$22M, a net margin of -14.5%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 12% a year, a 5-year average ROIC of -281%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 69% below the current price.

About Heron Therapeutics

Heron Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2016 to $155M in 2025, growth of about 70.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 8% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.4
P/B12.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-24.3%
Shareholder yield0.0%
Intrinsic value vs. price−69%

Growth and quality

Revenue growth (1 yr)7.4%
Revenue growth (5 yrs, per year)11.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-106.8%
ROIC (5-yr avg.)-281.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$148M$155M$144M$127M$108M$86M$89M$146M$77M$31M$1M
Net income-$22M-$20M-$14M-$111M-$182M-$221M-$227M-$205M-$179M-$197M-$173M
Free cash flow-$14M-$28M-$24M-$60M-$149M-$206M-$192M-$132M-$201M-$173M-$137M
EPS (diluted)$-0.11$-0.12$-0.09$-0.80$-1.67$-0.00$-0.00$-0.00$-0.00$-0.00$-0.00
Net margin-14.5%-13.0%-9.4%-87.0%-169.0%-255.6%-256.4%-140.3%-230.8%-641.9%-13537.4%
ROIC—-14.0%——-634.0%-195.6%-71.0%-39.8%-37.8%-117.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Heron Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 69% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Heron Therapeutics pay a dividend?

Not currently.

Is Heron Therapeutics a good stock to buy?

We do not give buy or sell advice. Heron Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.